Su1436 Olmesartan-Associated Sprue: A French National Study
Lysiane Marthey(Université Paris-Saclay), Franck Carbonnel(Université Paris-Saclay), Anne Druez(CHU Dinant Godinne UCL Namur), Nadine Cerf–Bensussan(Université Paris Cité), Philippe Pouderoux(Centre Hospitalier Universitaire de Nîmes), M. Gompel(Kennedy Clinic Hospital), Guillaume Cadiot(Centre Hospitalier Universitaire de Reims), M Eoche(Centre Hospitalier Universitaire Amiens-Picardie), P. Colardelle(Centre Hospitalier de Versailles), Véred Abitbol(Hôpital Cochin), Eric Poncin(Centre Hospitalier de Dax –Côte d’Argent), R Bobichon(Institut Catholique d'Arts et Métiers), David Parlier(Hôpital Ambroise-Paré), Florence Skinazi(Centre Hospitalier Saint-Denis), Philippe Seksik(Inserm), Georgia Malamut(Délégation Paris 5), B Mesnard(Centre Hospitalier de Tourcoing), Jean Alain Chayvialle, J. Lacroute, Éric Lerebours, Pauline Wils(Centre Oscar Lambret)
Cited by 0
Related Papers
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
|Annals of Oncology|2017|1.3k
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
|Nature Reviews Clinical Oncology|2016|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|Annals of Oncology|2015|897